The multidrug resistance (MDR), often conferred by the active extrusion of drugs from the cell, is a phenomenon often seen in cancer cells that may become resistant to a wide spectrum of drugs with varying chemical structures or cellular targets. This event has recently been reported for anticonvulsants. Studies in our laboratories on this occurrence with some enaminones have shown that the enaminones display high efflux ratios and are recognized by P-glycoprotein (P-gp) and/or the multidrug resistance protein (MRP), which have been reported as the main efflux transporters responsible for the development of MDR. Recent studies have uncovered interesting structural analog that can modulate the functional activity of P-gp, suggesting a possible increase in the bioavailabillity of P-gp substrate drugs when administered concurrently.
INTRODUCTION.
The phenomenon of multidrug resistance (MDR) has been known for a long time [1] [2] [3] [4] . It has been claimed to be the single most important reason for the failure of cancer treatment [5] . This major form of resistance against a variety of antineoplastic agents involves the function of a group of membrane proteins that expel the antineoplastic agents outside the cells, lowering the drug level to a non-killing level [1] . Human P-glycoprotein (P-gp) encoded by MDR1 and the multidrug resistance-associated protein (MRP1) are both members of the superfamily of ATP binding cassette (ABC) transporter proteins [6, 7] . This MDR1 gene product P-gp has been found to be present in tumor cells and due to its overexpression in these cells, allows for protection against several anticancer drugs, such as vinca alkaloids, etoposide and paclitaxel [8, 9] . While cells in culture can display drug resistance up to 1,000-fold greater than a sensitive phenotype, drug-resistant tumors isolated from patients generally exhibit only a 2-10-fold increase in drug resistance. Thus, relatively low levels of P-gp in tumors are thought to provide drug resistance in clinical oncology [10, 11] . The main function of this class of proteins is to transport a divergent group of both endogenous compounds as well as xenobiotics out of the cell [8] . Expression is highest in tissues with protective barrier functions such as the brush border of proximal tubules of the kidney, the bile canalicular membrane of hepatocytes, the apical membrane of mucosal cells in the intestine, the luminal surface of the secretory epithelium of the gravid uterus and the luminal membrane of endothelial cells at the blood-brain barrier sites [8] . Also, their presence in humans has been noted in drug resistance to other diseases, i.e. malaria and Acquired *Address correspondence to this author at the Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, USA; E-mail: kscott@howard.edu Immune Deficiency Syndrome (AIDS) [1] and in epilepsy [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Several reviews on this occurrence in epilepsy therapy have recently appeared [28] [29] [30] [31] .
MDR REVERSAL AGENTS
As reported by Berger et al. [11] , numerous diverse compounds were able to reverse MDR in vitro, and restoring effective cytotoxic concentrations of the anticancer agents. These compounds include: calcium channel antagonists (e.g. verapamil, 1) [32] ; dihydropyridines [33, 34] ; pyridine analogs [35] ; vinca alkaloid analogus [36] ; antiarrhythmic agents (e.g. quinidine, 2) [37] ; immunosuppressants (cyclosporin A) [38] ; phenoxazines [39] ; calmodulin antagonists (e.g. trifluoroperazine, 3) [40] ; triazines (S-9788, 4) [41] ; acridone carboxamides (GF-120918, 5) [42] ; and pipecolinates (VX-710, biricodar, 6) [43] . Fig. (1) provides these structures. The number in parenthesis represents the ClogP [44] . While clinical trials of these compounds and their analogs have been undertaken and displayed some benefit, their use has not been overwhelming [44] .
The Berger group did provide an interesting and effective series of MDR reversal agents and provided a useful SAR analysis [11] . Using the verapamil skeleton, a series of α-aryl-α-thioether-alkyl, -alkanenitrile, and alkanecarboxylic acid methyl ester tetrahydroisoquinoline and isoindoline derivatives were synthesized. From this series emerged 7 and 8. These compounds, especially 7, were effective modulators of MDR resulting from the overexpression of the MDR1 gene. This was demonstrated in selectively reversing the activity of hydrophobic anticancer agents such as vinblastine, bisantrene, colchicine, and doxorubicin. In addition, there was strong evidence that 7 interacts with Pgp [46] . It was concluded that 7 probably acts as a reversal agent by inhibiting the P-gp-mediated efflux of the cytotoxic agents, by blocking the ability of P-gp to interact with the anticancer agents. In the case of compounds, due to the hydrophobic nature of the anticancer agents, as noted by their ClogP values, it was proposed that the hydrophobic reversal agents 7 and 8 also bind to P-gp. Unlike verapamil and cyclosporin A, 7 was not effluxed from cells by P-gp, suggesting that it binds more strongly to or at a distinct site of the binding pocket [11] . Other synthetic studies on analogs of the dihydropyridines [47] , verapamil [48, 49] and cyclosporin A [50] as reversal agents have been reported.
The first clear structure activity correlation to the reversal agents has recently been reported [6] . Seelig and coworkers suggested that substrate recognition patterns for human P-gp encoded by MDR1 consists of two electron donor groups with a spatial separation of 2.5 ± 0.3 Å (type I units) or three electron donor groups with a spatial separation of the two outer groups of 4.6 ± 0.6 Å (type II units [51] . This is depicted in Fig. (2) . It was observed that P-gp and MRP1 have partially overlapping substrate specificity even though the proteins display only 15% homology [52] . Seelig hypothesized that P-gp most probably recognizes patterns of electron donor groups (or hydrogen bond acceptor groups) in these diverse reversal agents. These P-gp substrates consist of electron donor groups comprised of carbonyl-, ether-, hydroxy-, or tertiary amino groups, π-electron systems and A---B d istance = type I unit; A---C distance = type II unit Where A and B are two electron don or groups; and A and C are three electro n donor groups Fig. (2) . The Seelig hypothesis [6] for substrate recognition for human P-gp encoded by MDR1.
certain halides with the requisite spatial separation [6] . Thus, binding to P-gp could be predicted by the number and type I and type II units Further molecules, which contain at least one type II unit, were predicted to be inducers of P-gp overexpression. These conclusions were based on analysis of the transmembrane sequence of P-gp [53, 54] which show that for those areas with a relevant potential for interaction carry a high percentage of amino acid residues with hydrogen bond donor side chains. Seelig concluded that substrate recognition involved hydrogen bond formation with the electron donor (or hydrogen bond acceptor groups of the substrate) [52] . While the Berger groups [11] cited hydrophobicity of the molecule as the major determinant in reversal activity, Seelig indicated that activity resides not with this parameter, but neither binding nor transport is possible if a compound lacked electron donor groups. In addition, Seelig showed that in the case of compounds carrying an identical number of electron donor units; binding and transport would be proportional to hydrophobicity. Hydrophobicity, thus, is a modulator, not a determinant, of the substrate-transporter interaction.
1 Seeling [6] provides a quantitative notation to describe the electron unit: "A"
indicates strong (oxygen-containing) hydrogen bond accetor or electron donor groups, and "a" indicates weaker hydrogen bond acceptor groups such as tertiary amines, halides, sulfides, or π-electron systems.
Analysis of 21 compounds previously tested as MRP1 substrates were evaluated for electron donor groups or groups with a π-electron orbital of an unsaturated system. Employing molecular modeling techniques, these compounds were minimized and the 12 putative transmembrane domains of the human P-gp [55] and the 17 putative acid groups, i.e. O, N, S, or X=F, Cl, or groups with a π-electron orbital of an unsaturated and the structural distance between neighboring electron donor groups determined [6] . Then transmembrane domains of MRP1 [56, 57] were analyzed for their content of: (a) amino residues with hydrogen bonding side chains; (b) charged amino acid residues; and (c) amino residues with π-electron systems. The analysis of the 21 compounds were distinguished by: (a) inhibitors that were bound, but not transported across the membrane by MRP1; (b) weak substrates that were bound and transported only weakly by MRP1; and (c) substrates that were bound and transported efficiently by MRP1. For inhibitors, it was found that type I units were the determining factor, exemplified by sulfinpyrazone ( (9), and probenecid (10), Fig. (3) ). For weak substrates that were bound and transported, at least one electrically neutral type I unit together with one negatively charged type I unit or two electrically neutral type I units were required. For good substrates, they possessed up to six electron donor units of which up to four of these are negatively charged, exemplified Fig. (4) . Initial studies exploring the efflux mechanism [72, 74] . Numbers in parenthesis are the ClogP values [44] .
by the glutathione conjugate (14) (Fig. (3) ). In order to differentiate between the substrates for P-gp and MRP1, four compounds were examined: nifedipine (11), a P-gp substrate, flunitrazepam (12), a compound that binds to, but is not transported by P-gp, dinitrophenol (13), a compound that is a poor MRP1 substrate and the S-glutathione of 2,4-dinitrophenol (14) . It was concluded that: (1) nifedipine carries one nitro group and two ester groups, all three of which show type 1 geometry, however the two oxygen atoms of the nitro group have partial negative charges which do not favor P-gp binding as electron acceptor groups. This mesomeric substituent is overridden by the diester functionality, making nifedipine (11) both bound and transported by P-gp. However, flunitrazepam (12) , while also carrying a nitro group, the neutral electron donor groups, i.e. carbonyl and a tertiary amino group (and possibly with the halide and imino nitrogen) are weak. This makes flunitrazepam a borderline substrate for P-gp. The dinitrophenol (13), carrying two mesomeric electron donor substituents, is not a P-gp substrate. However the dinitro Sglutathione conjugate (14) is an effective MRP1 substrate. Daunorubicin (15) , an example of a substrate for both transporters, is electrically neutral, and contains one type I unit and two type II units. Daunorubicin has been shown to be a good P-gp substrate [58, 59] , but only a weak substrate for MRP1 [60] , however, it is increased by conjugation with glutathione [61] . Seelig concluded that although the two transport proteins P-gp and MRP1 both recognize type I units, the latter appears to directly interact with negatively charged type I units while the former does not [51] .
THE ENAMINONES AND THE EFFLUX SYSTEM
In our research on the enaminone system as anticonvulsants [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] , we have found several highly active unique entities. Critical evaluation of the physiochemical properties of various compounds has revealed that permeability and rate of transport across in vitro cell models is dependent on lipophilicity and molecular mass. In general, small molecular weight compounds (400-600 kDa), and which are lipophilic show a correlation to in situ/in vivo intestinal and blood-brain barrier (BBB) permeability [80, 81] . Using the established in vitro Bovine Brain Microvessel Endothelial (BBMEC) primary cell model, the transport of a small diverse set of enaminones (Fig. (4) ) was determined [72, 74] . Table 1 revealed that four of five enaminone analogues (i.e. methyl 4-(4-chlorophenylamino)-6-methyl-2-oxocyclohex-3-ene carboxylate 16, methyl 4-(3-nitrophenylamino)-6-methyl-2-oxocyclohex-3-enecarboxylate 1 7 , methyl 4-(4-cyanophenylamino)-6-methyl-2-oxocyclohex-3-ene carboxylate 18, and methyl 4-(3-trichloromethoxyphenylamino)-6-methyl-2-oxocyclohex-3-ene carboxylate 1 9 ), but not ethyl 4-[(5-methyl-3-isoxazolyl)amino)]-6-methyl-2-oxocyclohex-3-ene carboxylate, 20, exhibited significantly higher permeability from the basolateral to apical sides with efflux ratios ranging from 1.9 to 5.3 [72] . As seen in Table 2 , the preincubation of cell monolayers with verapamil, 1, a known MDR reversal agent, significantly reduced the efflux of 3 out of 4 compounds (i.e. 16, 17 and 19) [75] . Since multidrug resistance-associated protein (MRP) actively transports a broad range of anionic compounds out of the cell, including probenecid, 10, [82, 83] , the overexpression of P-gp alone does not completely explain intrinsic multidrug resistance or drug efflux and the multidrug resistance-associated proteins (MRP1, MRP2, MRP3, and MRP5), may be involved with the transport of the enaminones, distant members of the MDR family [82] [83] [84] [85] [86] [87] [88] . The presence of MRP1, MRP4, MRP5 and MRP6 in BBMECs has been reported [82, 89] . The possible role of MRP1 on enaminone transport was evaluated across BBMECs using probenecid, 10, as an MRP1 inhibitor [84] . Pre-incubation with probenecid significantly reduced the efflux of only one analog, 1 7 ( Table 2) .
To validate the results of the BBMEC studies with verapamil, we investigated the transport of the enaminones using a P-gp overexpressing cell line (i.e. MCF-7 and MCF-7/Adr). R123, a fluorescent probe, was used to predict the presence of an intrinsically active or chemotherapeutically induced P-gp drug efflux pump in tumor cells as well as overexpressing P-gp cell lines [80, 81] . As noted in Table 3 , two of four enaminones, 16 and 17, caused a statistically significant increase in the uptake of R123 when compared to uptake alone. Both 16 and 17 caused a statistically significant increase in the uptake of the fluorescent probe at both concentrations of R123 (3.2 and 5.0 µM). These results suggest that both 16 and 17 are substrates of P-gp.
Our results in vitro strongly suggested that the MDR proteins (i.e. P-gp and MRP1) influence the transport of enaminones across the BBB. As such, studies were performed to examine if P-gp or MRP altered the brain uptake of two enaminones, 16 and 17 by using mdr1a/1b (-/-), mdr1a/1b (+/+) mice and mdr1a/1b (+/+) mice pretreated with probenecid [74] . The mdr1ab(-/-) mice are genetically altered knockout mice that lack the gene needed for the expression of P-gp [90] . The distribution of enaminones in brain tissue of wild type, knockout and pretreated mice were evaluated by determining the concentration of drugs (i.e. 16, 17 and 19) in brain tissue via HPLC analysis [73] . (Table 4) . As the ratios depict, there were no time points that showed statistically significant increases in 17 in knockout brain or plasma concentrations as compared to their wild type counterparts. wild type and knockout mice are also depicted in Table 4 .
Compound 17 brain concentrations in knockout mice were significantly higher than wild type from 15, 30 and 90 minutes. In addition, significantly lower plasma concentrations were observed for 17 in the knockout animals. In vitro results suggested that for 17, either Pglycoprotein or MRP1 might be responsible for extrusion of this particular enaminone out of the CNS [74] . Therefore, probenecid, 10, an MRP1 substrate, utilized in several in vitro and in vivo models, was administered prior to the administration of 17 in wild type mice. Thus, wild type mice were pre-treated with the appropriate dose (100 mg kg -1 ) intraperitoneally 30 minutes before the administration of 17 (500 µg g -1 , iv). There were no time points that showed statistically significant increases in 17 wild type brain concentrations as compared to those pre-treated with probenecid ( Table 5) . As was noted for the mdr1ab (-/-) animals, 17 plasma concentrations were also significantly lower as compared to the wild type. Significantly higher brain-to-plasma ratios were found at most time points for the knockout and pre-treated animals vs. wild type.
Previous research evaluating the efficacy of antiepileptic agents, such as phenytoin, phenobarbital and lorazepam, has suggested that MDR1 gene expression may be responsible for drug-resistant epilepsy [12, 13] . Our in vitro results strongly suggest the influence of an MDR protein on enaminone permeability. In vivo analysis of the brain uptake of enaminones with genetically deficient mice lacking both genes responsible for the expression of P-gp showed a significant increase in the brain accumulation of two enaminones in mdr1a/b (-/-) knockout mice when compared to their wild type (+/+) counterparts. Hence, these results strongly suggest that P-gp may influence enaminone transport at the blood brain arrier and may play a significant role in the effective treatment of epilepsy.
O N H H Fig. (6) . The enaminone pharmacophore after Seelig [6] . Carbonyl oxygen =C:; vinyl hydrogen = A: N-H hydrogen B. Further studies on this phenomenon have been undertaken on a larger, diverse set of enaminones (Fig. (5) ) [91] 2 . This study was designed to use the enaminones to enhance oral drug bioavailability, and, consequently, therapeutic effectiveness. This current study was to: (1) investigate the potential inhibitory effect of various active and inactive enaminones (see Fig. (5) ) on the efflux of paclitaxel, a P-gp substrate drug; (2) identifythe optimal effective concentration of selected enaminones for inhibition of P-gp substrate's efflux; (3) compare the effect of these enaminones on paclitaxel efflux to the common P-gp modulator, cyclosporin A; and (4) investigate the effectiveness of these enaminones on paclitaxel absorption in vivo. The anticonvulsant activities of this data set varied from highly active (activity at < 100 mg kg - 1 : 1 6 ,  21,26,30,32,33, and 35-37 ) to active (activity between 100-300 mg kg -1 : 34) to inactive (no activity up to 300 mg kg -1 : 22, 25, 27-29, 31, and 38) . The apical to basolateral transport of [ 14 C]paclitaxel was determined in the presence of the enaminones in Fig. (5) across Caco-2 cells. The concentration-effect profiles for compounds 28 and 35, the two most active compounds, were conducted at concentrations ranging from 10 -4 to 10 -10 M across Caco-2 cells. Fig. (9) . Molecular surface area of compound 28 after Seelig [6] . Additionally, the effect of 35, with the best modulating activity in the paclitaxel studies on cyclosporin A transport across of a cells, was investigated over the same range of concentrations. Also, the effect of 35 on paclitaxel transport was compared to that of cyclosporin A. The results of these studies indicated a statistically significant (p<0.05) increase in the apical to basolateral apparent permeability coefficient [P app(A-B) ] of [ 14 C]paclitaxel, after incubation with either 24 or 30 at 10 -5 M, were with compounds 28 and 35 displaying 124.3% and 143.7% increases, respectively. The concentration-effect profiles for both analogs displayed a bell-shape pattern. Compound 35 caused a 360% increase in P app(A-B)Paclitaxel at 10 -6 M, while compound 28 displayed a 131% increase in P app(A-B)Paclitaxel at 10 -7 M. Compound 35 also caused a statistically significant increase in the transport of [cyclosporin A at 10 -7 M (139.2% increase in P app(A-B)Cyclosporin A ). Cyclosporin A (5 µM), a P-gp inhibitor, caused a 212.6% increase in P app(A-B)Paclitaxel . Although 35 did not cause an increase in the paclitaxel plasma concentration profiles when administered intraduodenally to rats, statistically significant amounts of radiolabeled paclitaxel were quantitated in the brains of the treated group. These studies suggest that the enaminones are a novel and potent group of P-gp modulators, which may improve the efficacy of conventional therapy when used in combination with therapeutic P-gp substrate agents. The complete study of this research has been accepted [91] .
Structurally, the enaminones provide extensive charge delocalization involving the nitrogen atom and the carbonyl oxygen [92] . This factor compares favorably to the Seelig model [6] . The template for these two compounds is shown in Fig. (6) . Thus, compounds 28 and 35 were drawn and minimized [93] . These structures are shown in Fig. (7) . (28) and 8 (35) . Their bond distances are summarized in Table 6 .
Figs. (9) and 10 delineate the Connolly molecular area of 712.08 Å 2 for 28 and 392.88 Å 2 for 35, respectively. As noted there is excellent agreement with the bond distances and lipophilicity. Fig. (10) . Molecular surface area of compound 35 after Seelig [6] .
